End-Stage Liver Disease in a State Prison Population

Jacques Baillargeon, Roger D. Soloway, David Paar, Thomas P. Giordano, Owen Murray, James Grady, Brie Williams, John Pulvino, Benny Raimer

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: Information on the epidemiology of end-stage liver disease (ESLD) in US correctional populations is limited. We examined the prevalence, mortality and clinical characteristics of ESLD in the nation's second largest state prison system. Methods: We collected and analyzed medical and demographic data from 370,511 offenders incarcerated in Texas' prison system during a 3.5-year period. Results: ESLD was diagnosed in 484 inmates (131/100,000); 213 (57/100,000) died of ESLD. Offenders who were Hispanic, 30-49 years of age, ≥50 years of age, HIV monoinfected, hepatitis C virus (HCV) monoinfected, or HIV/HCV coinfected had elevated ESLD prevalence and mortality rates. Conclusions: ESLD mortality in Texas' prison population is approximately 3 times higher than that of the general population, reflecting elevated rates of HCV and HIV/HCV coinfection among prisoners. Ultimately, the only viable treatment option for many prisoners with ESLD will be liver transplantation. The enormous costs of organ transplantation and immunosuppressive therapy are staggering and have the potential to decimate the healthcare budgets of most prison systems. Consequently, it is imperative that correctional healthcare programs expand HCV treatment and prevention strategies.

Original languageEnglish (US)
Pages (from-to)808-813
Number of pages6
JournalAnnals of Epidemiology
Volume17
Issue number10
DOIs
StatePublished - Oct 2007

Fingerprint

End Stage Liver Disease
Prisons
Hepacivirus
Population
Prisoners
HIV
Mortality
Delivery of Health Care
Organ Transplantation
Budgets
Immunosuppressive Agents
Coinfection
Hispanic Americans
Liver Transplantation
Epidemiology
Therapeutics
Demography
Costs and Cost Analysis

Keywords

  • End-Stage Liver Disease
  • Hepatitis C
  • HIV
  • Prisons

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

End-Stage Liver Disease in a State Prison Population. / Baillargeon, Jacques; Soloway, Roger D.; Paar, David; Giordano, Thomas P.; Murray, Owen; Grady, James; Williams, Brie; Pulvino, John; Raimer, Benny.

In: Annals of Epidemiology, Vol. 17, No. 10, 10.2007, p. 808-813.

Research output: Contribution to journalArticle

Baillargeon, J, Soloway, RD, Paar, D, Giordano, TP, Murray, O, Grady, J, Williams, B, Pulvino, J & Raimer, B 2007, 'End-Stage Liver Disease in a State Prison Population', Annals of Epidemiology, vol. 17, no. 10, pp. 808-813. https://doi.org/10.1016/j.annepidem.2007.04.005
Baillargeon, Jacques ; Soloway, Roger D. ; Paar, David ; Giordano, Thomas P. ; Murray, Owen ; Grady, James ; Williams, Brie ; Pulvino, John ; Raimer, Benny. / End-Stage Liver Disease in a State Prison Population. In: Annals of Epidemiology. 2007 ; Vol. 17, No. 10. pp. 808-813.
@article{3ad1c7f6505548f0b76043dbcafb6b54,
title = "End-Stage Liver Disease in a State Prison Population",
abstract = "Objectives: Information on the epidemiology of end-stage liver disease (ESLD) in US correctional populations is limited. We examined the prevalence, mortality and clinical characteristics of ESLD in the nation's second largest state prison system. Methods: We collected and analyzed medical and demographic data from 370,511 offenders incarcerated in Texas' prison system during a 3.5-year period. Results: ESLD was diagnosed in 484 inmates (131/100,000); 213 (57/100,000) died of ESLD. Offenders who were Hispanic, 30-49 years of age, ≥50 years of age, HIV monoinfected, hepatitis C virus (HCV) monoinfected, or HIV/HCV coinfected had elevated ESLD prevalence and mortality rates. Conclusions: ESLD mortality in Texas' prison population is approximately 3 times higher than that of the general population, reflecting elevated rates of HCV and HIV/HCV coinfection among prisoners. Ultimately, the only viable treatment option for many prisoners with ESLD will be liver transplantation. The enormous costs of organ transplantation and immunosuppressive therapy are staggering and have the potential to decimate the healthcare budgets of most prison systems. Consequently, it is imperative that correctional healthcare programs expand HCV treatment and prevention strategies.",
keywords = "End-Stage Liver Disease, Hepatitis C, HIV, Prisons",
author = "Jacques Baillargeon and Soloway, {Roger D.} and David Paar and Giordano, {Thomas P.} and Owen Murray and James Grady and Brie Williams and John Pulvino and Benny Raimer",
year = "2007",
month = "10",
doi = "10.1016/j.annepidem.2007.04.005",
language = "English (US)",
volume = "17",
pages = "808--813",
journal = "Annals of Epidemiology",
issn = "1047-2797",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - End-Stage Liver Disease in a State Prison Population

AU - Baillargeon, Jacques

AU - Soloway, Roger D.

AU - Paar, David

AU - Giordano, Thomas P.

AU - Murray, Owen

AU - Grady, James

AU - Williams, Brie

AU - Pulvino, John

AU - Raimer, Benny

PY - 2007/10

Y1 - 2007/10

N2 - Objectives: Information on the epidemiology of end-stage liver disease (ESLD) in US correctional populations is limited. We examined the prevalence, mortality and clinical characteristics of ESLD in the nation's second largest state prison system. Methods: We collected and analyzed medical and demographic data from 370,511 offenders incarcerated in Texas' prison system during a 3.5-year period. Results: ESLD was diagnosed in 484 inmates (131/100,000); 213 (57/100,000) died of ESLD. Offenders who were Hispanic, 30-49 years of age, ≥50 years of age, HIV monoinfected, hepatitis C virus (HCV) monoinfected, or HIV/HCV coinfected had elevated ESLD prevalence and mortality rates. Conclusions: ESLD mortality in Texas' prison population is approximately 3 times higher than that of the general population, reflecting elevated rates of HCV and HIV/HCV coinfection among prisoners. Ultimately, the only viable treatment option for many prisoners with ESLD will be liver transplantation. The enormous costs of organ transplantation and immunosuppressive therapy are staggering and have the potential to decimate the healthcare budgets of most prison systems. Consequently, it is imperative that correctional healthcare programs expand HCV treatment and prevention strategies.

AB - Objectives: Information on the epidemiology of end-stage liver disease (ESLD) in US correctional populations is limited. We examined the prevalence, mortality and clinical characteristics of ESLD in the nation's second largest state prison system. Methods: We collected and analyzed medical and demographic data from 370,511 offenders incarcerated in Texas' prison system during a 3.5-year period. Results: ESLD was diagnosed in 484 inmates (131/100,000); 213 (57/100,000) died of ESLD. Offenders who were Hispanic, 30-49 years of age, ≥50 years of age, HIV monoinfected, hepatitis C virus (HCV) monoinfected, or HIV/HCV coinfected had elevated ESLD prevalence and mortality rates. Conclusions: ESLD mortality in Texas' prison population is approximately 3 times higher than that of the general population, reflecting elevated rates of HCV and HIV/HCV coinfection among prisoners. Ultimately, the only viable treatment option for many prisoners with ESLD will be liver transplantation. The enormous costs of organ transplantation and immunosuppressive therapy are staggering and have the potential to decimate the healthcare budgets of most prison systems. Consequently, it is imperative that correctional healthcare programs expand HCV treatment and prevention strategies.

KW - End-Stage Liver Disease

KW - Hepatitis C

KW - HIV

KW - Prisons

UR - http://www.scopus.com/inward/record.url?scp=34548589094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548589094&partnerID=8YFLogxK

U2 - 10.1016/j.annepidem.2007.04.005

DO - 10.1016/j.annepidem.2007.04.005

M3 - Article

VL - 17

SP - 808

EP - 813

JO - Annals of Epidemiology

JF - Annals of Epidemiology

SN - 1047-2797

IS - 10

ER -